Balak et al. [11] examined tumor cells from 16 patients with acquired drug-resistant lung cancer by molecular analysis; in about 50% of these cases, resistance was due to the occurrence of a secondary mutation in EGFR (T790M). This evidence concerns the gene EGFR and lung carcinoma.